Back to School: How biopharma can reboot drug development. Access exclusive analysis here

HuMax-CD20 Ofatumumab: Phase III started

The partners began an international Phase III trial (GEN411/OFA110634) in about

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE